Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic Institute
Purpose. To compare the diagnostic accuracy of hepatospecific contrast-enhanced MRI versus triple-phase CT scan after radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) patients. Methods. Thirty-four consecutive HCC patients (42 hepatic nodules) were treated with percutaneous RFA and un...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2013/469097 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551994506608640 |
|---|---|
| author | Vincenza Granata Mario Petrillo Roberta Fusco Sergio Venanzio Setola Elisabetta de Lutio di Castelguidone Orlando Catalano Mauro Piccirillo Vittorio Albino Francesco Izzo Antonella Petrillo |
| author_facet | Vincenza Granata Mario Petrillo Roberta Fusco Sergio Venanzio Setola Elisabetta de Lutio di Castelguidone Orlando Catalano Mauro Piccirillo Vittorio Albino Francesco Izzo Antonella Petrillo |
| author_sort | Vincenza Granata |
| collection | DOAJ |
| description | Purpose. To compare the diagnostic accuracy of hepatospecific contrast-enhanced MRI versus triple-phase CT scan after radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) patients. Methods. Thirty-four consecutive HCC patients (42 hepatic nodules) were treated with percutaneous RFA and underwent MR and CT scans. All patients were enrolled in a research protocol that included CT with iodized contrast medium injection and MR with hepatospecific contrast medium injection. All patients were restaged within four weeks and at 3 months from ablation. The images were reviewed by four different radiologists to evaluate tumor necrosis, residual or recurrence disease, and evidence of new foci. Results. Thirty-two nodules were necrotic after treatment; 10 showed residual disease. Six new HCCs were identified. At first month followup CT has identified 34 necrotic lesions and 8 residual diseases; no new foci were recognized. At MRI instead, 32 complete necrotic lesions were identified, 10 lesions showed residual disease, and 2 new HCCs were found. At three months, CT demonstrated 33 completely necrotic lesions, 9 residual diseases, and 2 new HCCs. MR showed 31 complete necrotic lesions, 11 cases of residual disease, and 6 new HCCs. Conclusions. Hepatospecific contrast-enhanced MRI is more effective than multiphase CT in assessment of HCC treated with RFA. |
| format | Article |
| id | doaj-art-0feed454609e45bf9fa7f5e43e26e902 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-0feed454609e45bf9fa7f5e43e26e9022025-02-03T05:59:46ZengWileyGastroenterology Research and Practice1687-61211687-630X2013-01-01201310.1155/2013/469097469097Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic InstituteVincenza Granata0Mario Petrillo1Roberta Fusco2Sergio Venanzio Setola3Elisabetta de Lutio di Castelguidone4Orlando Catalano5Mauro Piccirillo6Vittorio Albino7Francesco Izzo8Antonella Petrillo9Division of Radiology, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyDivision of Radiology, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyDivision of Radiology, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyDivision of Radiology, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyDivision of Radiology, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyDivision of Radiology, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyDivision of Hepato-Biliary Surgery, Department of Abdominal Oncology, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyDivision of Hepato-Biliary Surgery, Department of Abdominal Oncology, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyDivision of Hepato-Biliary Surgery, Department of Abdominal Oncology, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyDivision of Radiology, Department of Diagnostic Imaging, Radiant and Metabolic Therapy, “Istituto Nazionale Tumori Fondazione Giovanni Pascale-IRCCS”, Via Mariano Semmola, 80131 Naples, ItalyPurpose. To compare the diagnostic accuracy of hepatospecific contrast-enhanced MRI versus triple-phase CT scan after radiofrequency ablation (RFA) in hepatocellular carcinoma (HCC) patients. Methods. Thirty-four consecutive HCC patients (42 hepatic nodules) were treated with percutaneous RFA and underwent MR and CT scans. All patients were enrolled in a research protocol that included CT with iodized contrast medium injection and MR with hepatospecific contrast medium injection. All patients were restaged within four weeks and at 3 months from ablation. The images were reviewed by four different radiologists to evaluate tumor necrosis, residual or recurrence disease, and evidence of new foci. Results. Thirty-two nodules were necrotic after treatment; 10 showed residual disease. Six new HCCs were identified. At first month followup CT has identified 34 necrotic lesions and 8 residual diseases; no new foci were recognized. At MRI instead, 32 complete necrotic lesions were identified, 10 lesions showed residual disease, and 2 new HCCs were found. At three months, CT demonstrated 33 completely necrotic lesions, 9 residual diseases, and 2 new HCCs. MR showed 31 complete necrotic lesions, 11 cases of residual disease, and 6 new HCCs. Conclusions. Hepatospecific contrast-enhanced MRI is more effective than multiphase CT in assessment of HCC treated with RFA.http://dx.doi.org/10.1155/2013/469097 |
| spellingShingle | Vincenza Granata Mario Petrillo Roberta Fusco Sergio Venanzio Setola Elisabetta de Lutio di Castelguidone Orlando Catalano Mauro Piccirillo Vittorio Albino Francesco Izzo Antonella Petrillo Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic Institute Gastroenterology Research and Practice |
| title | Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic Institute |
| title_full | Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic Institute |
| title_fullStr | Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic Institute |
| title_full_unstemmed | Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic Institute |
| title_short | Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic Institute |
| title_sort | surveillance of hcc patients after liver rfa role of mri with hepatospecific contrast versus three phase ct scan experience of high volume oncologic institute |
| url | http://dx.doi.org/10.1155/2013/469097 |
| work_keys_str_mv | AT vincenzagranata surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute AT mariopetrillo surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute AT robertafusco surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute AT sergiovenanziosetola surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute AT elisabettadelutiodicastelguidone surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute AT orlandocatalano surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute AT mauropiccirillo surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute AT vittorioalbino surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute AT francescoizzo surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute AT antonellapetrillo surveillanceofhccpatientsafterliverrfaroleofmriwithhepatospecificcontrastversusthreephasectscanexperienceofhighvolumeoncologicinstitute |